AAAAAA

   
Results: 1-16 |
Results: 16
PHARMACODYNAMICS AND TOLERANCE OF 2 NADROPARIN FORMULATIONS (10,250 AND 20,500 ANTI XA IU-ML(-1)) DELIVERED FOR 10 DAYS AT THERAPEUTIC DOSE
Authors: BONEU B NAVARRO C CAMBUS JP CAPLAIN H DAZEMAR P NECCIARI J DURET JP GAUD C SIE P
Citation: B. Boneu et al., PHARMACODYNAMICS AND TOLERANCE OF 2 NADROPARIN FORMULATIONS (10,250 AND 20,500 ANTI XA IU-ML(-1)) DELIVERED FOR 10 DAYS AT THERAPEUTIC DOSE, Thrombosis and haemostasis, 79(2), 1998, pp. 338-341
LACK OF BIOEQUIVALENCE OF A GENERIC MEFLOQUINE TABLET WITH THE STANDARD PRODUCT
Authors: WEIDEKAMM E RUSING G CAPLAIN H SORGEL F CREVOISIER C
Citation: E. Weidekamm et al., LACK OF BIOEQUIVALENCE OF A GENERIC MEFLOQUINE TABLET WITH THE STANDARD PRODUCT, European Journal of Clinical Pharmacology, 54(8), 1998, pp. 615-619
MIZOLASTINE, A NEW H-1 ANTAGONIST, DOES NOT AFFECT THE CARDIAC REPOLARIZATION IN HEALTHY-VOLUNTEERS
Authors: CHAFOUR S CAPLAIN H LILIENTHAL N LHERITIER C DESCHAMPS C ROSENZWEIG P
Citation: S. Chafour et al., MIZOLASTINE, A NEW H-1 ANTAGONIST, DOES NOT AFFECT THE CARDIAC REPOLARIZATION IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 27-27
SAFETY AND PHARMACODYNAMIC STUDY OF BEFLOXATONE (B) AFTER FLUOXETINE (F) WITHDRAWAL
Authors: PINQUIER JL CAPLAIN H DURRIEU G ZIELENIUK I ROSENZWEIG P
Citation: Jl. Pinquier et al., SAFETY AND PHARMACODYNAMIC STUDY OF BEFLOXATONE (B) AFTER FLUOXETINE (F) WITHDRAWAL, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 60-60
COMPARISON OF THE BIOAVAILABILITY OF 2 NADROPARIN FORMULATIONS (10000AND 20000 ANTI-XA IU.ML-1) IN HEALTHY-YOUNG VOLUNTEERS
Authors: BONEU B NAVARRO C CAMBUS JP CAPLAIN H DAZEMAR P NECCIARI J DURET JP GAUD C SIE P
Citation: B. Boneu et al., COMPARISON OF THE BIOAVAILABILITY OF 2 NADROPARIN FORMULATIONS (10000AND 20000 ANTI-XA IU.ML-1) IN HEALTHY-YOUNG VOLUNTEERS, Thrombosis and haemostasis, 1997, pp. 1160-1160
EFFECTS OF A 24 HOURS INFUSION OF ARGATROBAN IN HEALTHY-VOLUNTEERS
Authors: BERGOUGNAN L CAPLAIN H BROHIER S DUBRUC C CABANIS MJ ROSENZWEIG P
Citation: L. Bergougnan et al., EFFECTS OF A 24 HOURS INFUSION OF ARGATROBAN IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 36-36
INHIBITION OF HISTAMINE-INDUCED SKIN WHEAL AND FLARE AFTER 5 DAYS OF MIZOLASTINE
Authors: PINQUIER JL CAPLAIN H CABANIS MJ DUBRUC C STALLABOURDILLON A ROSENZWEIG P
Citation: Jl. Pinquier et al., INHIBITION OF HISTAMINE-INDUCED SKIN WHEAL AND FLARE AFTER 5 DAYS OF MIZOLASTINE, Journal of clinical pharmacology, 36(1), 1996, pp. 72-78
COMPARATIVE DISPOSITION OF ENOXAPARIN IN TOTAL HIP-REPLACEMENT (THR) PATIENTS AND IN HEALTHY-VOLUNTEERS GIVEN SUBCUTANEOUSLY A 30 MG ENOXAPARIN DOSE 2 TIMES DAY FOR 7 DAYS
Authors: COLLIGNON F SAHA A OZOUX ML FURMAN WK SPIRO I MCCORMACK A CAPLAIN H THEBAULT JJ FRYDMAN A BOUTHIER J
Citation: F. Collignon et al., COMPARATIVE DISPOSITION OF ENOXAPARIN IN TOTAL HIP-REPLACEMENT (THR) PATIENTS AND IN HEALTHY-VOLUNTEERS GIVEN SUBCUTANEOUSLY A 30 MG ENOXAPARIN DOSE 2 TIMES DAY FOR 7 DAYS, Thrombosis and haemostasis, 73(6), 1995, pp. 970-970
DO THE PHARMACOKINETICS OF ENOXAPARIN REMAIN STABLE AND LINEAR IN THERANGE OF DOSES FOR PREVENTION UP TO THE RANGE OF DOSES FOR TREATMENT OF VENOUS THROMBOEMBOLIC DISEASES
Authors: FRYDMAN A BARA L COLLIGNON F OZOUX ML LEROUX Y COURNOT A THEBAULT JJ CAPLAIN H SAMAMA MM
Citation: A. Frydman et al., DO THE PHARMACOKINETICS OF ENOXAPARIN REMAIN STABLE AND LINEAR IN THERANGE OF DOSES FOR PREVENTION UP TO THE RANGE OF DOSES FOR TREATMENT OF VENOUS THROMBOEMBOLIC DISEASES, Thrombosis and haemostasis, 73(6), 1995, pp. 971-971
COMPARISON OF THE PHARMACOKINETIC PROFILES OF 3 LOW-MOLECULAR-MASS HEPARINS - DALTEPARIN, ENOXAPARIN AND NADROPARIN - ADMINISTERED SUBCUTANEOUSLY IN HEALTHY-VOLUNTEERS (DOSES FOR PREVENTION OF THROMBOEMBOLISM)
Authors: COLLIGNON F FRYDMAN A CAPLAIN H OZOUX ML LEROUX Y BOUTHIER J THEBAULT JJ
Citation: F. Collignon et al., COMPARISON OF THE PHARMACOKINETIC PROFILES OF 3 LOW-MOLECULAR-MASS HEPARINS - DALTEPARIN, ENOXAPARIN AND NADROPARIN - ADMINISTERED SUBCUTANEOUSLY IN HEALTHY-VOLUNTEERS (DOSES FOR PREVENTION OF THROMBOEMBOLISM), Thrombosis and haemostasis, 73(4), 1995, pp. 630-640
COMPARATIVE WHEAL AND FLARE STUDY OF MIZOLASTINE VS TERFENADINE, CETIRIZINE, LORATADINE AND PLACEBO IN HEALTHY-VOLUNTEERS
Authors: ROSENZWEIG P CAPLAIN H CHAUFOUR S ULLIAC N CABANIS MJ THEBAULT JJ
Citation: P. Rosenzweig et al., COMPARATIVE WHEAL AND FLARE STUDY OF MIZOLASTINE VS TERFENADINE, CETIRIZINE, LORATADINE AND PLACEBO IN HEALTHY-VOLUNTEERS, British journal of clinical pharmacology, 40(5), 1995, pp. 459-465
MULTIPLE-DOSE PHARMACOKINETICS AND DISTRIBUTION IN TISSUE OF TERBINAFINE AND METABOLITES
Authors: KOVARIK JM MUELLER EA ZEHENDER H DENOUEL J CAPLAIN H MILLERIOUX L
Citation: Jm. Kovarik et al., MULTIPLE-DOSE PHARMACOKINETICS AND DISTRIBUTION IN TISSUE OF TERBINAFINE AND METABOLITES, Antimicrobial agents and chemotherapy, 39(12), 1995, pp. 2738-2741
THE EFFECT OF SUBCUTANEOUS INJECTION OF UNFRACTIONATED AND LAW MOLECULAR-WEIGHT HEPARIN ON THROMBIN GENERATION IN PLATELET-RICH PLASMA - A STUDY IN HUMAN VOLUNTEERS
Authors: BENDETOWICZ AV KAI H KNEBEL R CAPLAIN H HEMKER HC LINDHOUT T BEGUIN S
Citation: Av. Bendetowicz et al., THE EFFECT OF SUBCUTANEOUS INJECTION OF UNFRACTIONATED AND LAW MOLECULAR-WEIGHT HEPARIN ON THROMBIN GENERATION IN PLATELET-RICH PLASMA - A STUDY IN HUMAN VOLUNTEERS, Thrombosis and haemostasis, 72(5), 1994, pp. 705-712
PHARMACOKINETICS AND PHARMACODYNAMICS OF A LOW-MOLECULAR-WEIGHT HEPARIN (ENOXAPARIN) AFTER SUBCUTANEOUS INJECTION, COMPARISON WITH UNFRACTIONATED HEPARIN - A 3 WAY CROSS-OVER STUDY IN HUMAN VOLUNTEERS
Authors: BENDETOWICZ AV BEGUIN S CAPLAIN H HEMKER HC
Citation: Av. Bendetowicz et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF A LOW-MOLECULAR-WEIGHT HEPARIN (ENOXAPARIN) AFTER SUBCUTANEOUS INJECTION, COMPARISON WITH UNFRACTIONATED HEPARIN - A 3 WAY CROSS-OVER STUDY IN HUMAN VOLUNTEERS, Thrombosis and haemostasis, 71(3), 1994, pp. 305-313
COMPARATIVE CLEARANCE PROFILE OF ENOXAPARIN AND UNFRACTIONATED HEPARIN IN MAN GIVEN BOTH MEDICATIONS BY THE SUBCUTANEOUS ROUTE
Authors: BARA L BENDETOWICZ AV CAPLAIN H COLLIGNON F LEROUX Y BOUTHIER J THEBAULT JJ FRYDMAN A SAMAMA MM
Citation: L. Bara et al., COMPARATIVE CLEARANCE PROFILE OF ENOXAPARIN AND UNFRACTIONATED HEPARIN IN MAN GIVEN BOTH MEDICATIONS BY THE SUBCUTANEOUS ROUTE, Thrombosis and haemostasis, 69(6), 1993, pp. 768-768
COMPARATIVE PHARMACOKINETICS OF ENOXAPARIN [LOVENOX-ASTERISK, CLEXANE-ASTERISK] (30-MG BID) AND UNFRACTIONATED HEPARIN (5,000-U TID) DURINGREPEATED SUBCUTANEOUS ADMINISTRATION IN MAN
Authors: COLLIGNON F OZOUX ML FRYDMAN A CAPLAIN H LEROUX Y KAPLAN P THEBAULT JJ BOUTHIER J
Citation: F. Collignon et al., COMPARATIVE PHARMACOKINETICS OF ENOXAPARIN [LOVENOX-ASTERISK, CLEXANE-ASTERISK] (30-MG BID) AND UNFRACTIONATED HEPARIN (5,000-U TID) DURINGREPEATED SUBCUTANEOUS ADMINISTRATION IN MAN, Thrombosis and haemostasis, 69(6), 1993, pp. 859-859
Risultati: 1-16 |